Introduction: Cervical cancer rates vary across the world, being highest in Eastern Africa (including Zimbabwe) and lowest in Western Asia. It is the second most common type of cancer in women in the South East Asia region and a major cause of cancer deaths among women of low and middle income countries (LMICs) like Nepal. This review is an attempt to make a comprehensive report of prevalence, incidence and mortality of cervical cancer in LMICs.
Introduction
Cervical cancer occurs in the lower part of the uterus that connects to the vagina; in the cells of the cervix (Fritz et al., 2000) . Recent global figures estimate 527,624 new cases and 265,672 deaths due to cervical cancer annually. Cervical cancer rates are highest in Eastern Africa (including Zimbabwe) and lowest in Western Asia. However, it is the second most common type of cancer in women in the South East Asia region and the major cause of cancer deaths among women of low and middle income countries (LMICs) like Nepal. International Agency for Research on Cancer (IARC, 2012) estimated age standardized incidence rate of cervical cancer as 19.0 per 100,000 and age standardized mortality rate as 12.0 per 100,000 in Nepal (Ferlay et al., 2013) .
Studies have shown that sexual behavior at an early age and increasing incidence of human papillomavirus (HPV) infection cause cervical cancer incidence to increase among younger women (Bosch et al., 1995) . Studies have estimated that over 80% of sexually active women will be infected with genital HPV at some point in their lifetime (Syrjanen et al., 1990) . Oncogenic HPV infection is the major etiological agent of cervical cancer of which70% are caused by HPV-16 and HPV-18 type (Munoz et al., 2004; Schiffman et al., 2007) .
In spite of the high disease burden, there are limited numbers of studies conducted on prevalence, incidence and mortality of cervical cancer in LMICs and no systematic review exists in this field. Our aim is to investigate the prevalence, incidence, mortality and major risk factors of cervical cancer reported by articles published in the period from 1st Jan 2000 to 31st Dec 2015 in LMICs. We believe this systematic review will constitute valuable reference materials for epidemiologists, health policy makers and researchers on cervical cancer.
Materials and Methods

Design
We conducted the review applying a computerized systematic search to identify the prevalence, incidence and mortality of cervical cancer in LMICs. The inclusion criteria of articles were: original article, studies reporting prevalence, incidence, and mortality rates, articles in English and studies conducted on humans. Figure 1 describes the inclusion and exclusion criteria as well as extraction process.
Data extraction
We performed a three-stage selection for data extraction. In the first stage, a search of the online Medical Literature Analysis and Retrieval System (MEDLINE) database was performed with a combination of Medical Subject Heading (MeSH) terms: "Cervical Cancer" and "Cervical Neoplasm" as major topics and "Epidemiology", ("prevalence" OR "incidence" OR "mortality") and "HPV" OR "Human papillomavirus" as subheadings. A similar search was also performed in Scopus and CINAHL. The search limits were: language ("English"), dates (articles published from "1st January 2000 to 31st December 2015"), and species ("Humans"). A total of 21,444 articles were obtained from these searches.
Furthermore, the result was narrowed down by adding the name of each LMIC as defined by the World Bank. According to the latest revision of World Bank, a total of 135 countries are listed as LMICs (The World Bank, 2016) . Thus at the end of first stage, we obtained 2413 specific articles.
In the second stage we reviewed titles and abstracts using predefined screening criteria. Exclusion criteria were: studies outside of LMICs, studies with no information about cervical cancer, reviews, reports, and duplicates. If the required information was not available in the abstract, we stopped reviewing further. Studies not satisfying the inclusion criteria were excluded at this stage.
In the third stage, we used the following exclusion criteria for further filtering the 190 papers from stage two: full text not in English, full text not available, not prevalence/ incidence/ mortality study, study reporting pre-cancer. Finally, we obtained 20 papers which were selected for further review and analysis (Figure 1 ). The characteristics recorded for each study included: country of origin, author's name and year of publication, study duration, age group, cervical cancer prevalence per 1000 per year, crude incidence, age standardized incidence rate, crude mortality, age standardized mortality rate per 100,000 per year and classification of cancer.
Ethical consideration
This article is based on published data, and hence ethical approval is not required.
Result
Characteristics of the studies
Detailed characteristics of the articles are presented in Table 1 . The 20 articles that were included in the analysis were from 15 countries: Brazil (N=2) (Kalakun and Bozzetti, 2005; Gonzaga et al., 2013) , China (N=3) (Chen, 2006; Du et al., 2015; Wang, 2015) , Colombia (N=1) (Pineros et al., 2013) , Cote D' Ivore (N=1) (Echimane et al., 2000) , Fiji (N=1) (Kuehn et al., 2012) , India (N=2) (Dhillon et al., 2011; Dikshit et al., 2012) , Jamaica (N=1) (Gibson et al., 2008) , Malawi (N=1) (Banda et al., 2001) , Mongolia (N=1) (Sandagdorj et al., 2010) , Nigeria (N=1) (Durowade et al., 2012) , Serbia (N=1) (Naumovic et al., 2015) , Thailand (N=1) (Sriamporn et al., 2003) , Tunisia (N=1) (Missaoui et al., 2010) , Uganda (N=1) (Wabinga, 2002) and Zimbabwe (N=2) (Chokunonga et al., 2000; Chokunonga et al., 2013) .
Cervical cancer prevalence and risk factor
Only one study reported prevalence as 5.0 per 1000 in 2012 (Durowade et al., 2012) in Nigeria. In addition, the study reported coitarche, tobacco smoking, number of sexual partners and family history of cervical cancer as significant risk factors (Durowade et al., 2012) .
Cervical cancer incidence
Ten studies reported cervical cancer crude incidence (Chokunonga et al., 2000; Echimane et al., 2000; Banda et al., 2001; Sriamporn et al., 2003; Chen, 2006; Gibson et al., 2008; Missaoui et al., 2010; Sandagdorj et al., 2010; Du et al., 2015; Wang, 2015) whereas 12 studies reported age standardized incidence rate (Chokunonga et al., 2000; Banda et al., 2001; Wabinga, 2002; Sriamporn et al., 2003; Chen, 2006; Gibson et al., 2008; Missaoui et al., 2010; Sandagdorj et al., 2010; Dhillon et al., 2011; Kuehn et al., 2012; Chokunonga et al., 2013; Du et al., 2015) . The crude incidence rate was reported highest as 13.4/100,000/year in 2015 (Du et al., 2015) and lowest as 0.14/100,000/year in 2006 (Chen, 2006) , 2015) . The crude mortality rate was reported highest as 12.71/100,000/year in 2015 in Serbia (Naumovic et al., 2015) and lowest as 0.1/100,000/year in 2015 in China (Wang, 2015) (Figure 3 ). Age standardized mortality rate was reported highest as 16/100,000/year in India in 2015 (Dikshit et al., 2012) and lowest as 1.8/100,000/year in Colombia in 2013 (Pineros et al., 2013) .
Discussion
This review is the first comprehensive report of prevalence, incidence and mortality of cervical cancer in LMICs. Among the 20 studies reviewed; seven studies were from Africa (Chokunonga et al., 2000; Echimane et al., 2000; Banda et al., 2001; Wabinga, 2002; Gibson et al., 2008; Missaoui et al., 2010; Durowade et al., 2012; Chokunonga et al., 2013) , seven from Asia (Sriamporn et al., 2003; Chen, 2006; Sandagdorj et al., 2010; Dhillon et al., 2011; Dikshit et al., 2012; Du et al., 2015; Wang, 2015) , three studies were from South America (Kalakun and Bozzetti, 2005; Gonzaga et al., 2013) ; (Pineros et al., 2013) one study from North America (Gibson et al., 2008) one from Europe (Naumovic et al., 2015) and one from Oceania (Kuehn et al., 2012) . The findings of the review give a strong imperative for further studies on cervical cancer prevalence, incidence and mortality in LMICs, where the disease burden is substantial.
Only one study, one from Nigeria reported prevalence as 5.0 per 1,000 in 2012 in age group 25-64 (Durowade et al., 2012) . Whereas, the IARC country specific estimate for cervical cancer prevalence for Nigeria was 15.6 per 1,000 per year (Bray et al., 2013) . Further, the study from Nigeria reported coitarche, tobacco smoking, number of sexual partners and family history of cervical cancer as significant risk factors (Durowade et al., 2012) . There is strong epidemiologic evidence indicating that HPV is the major etiology of cervical cancer (Bosch et al., 1995; Chichareon et al., 1998) . In addition, the onset of sexual intercourse at an early age and a greater number of lifetime sexual partners raises the risk of cervical cancer (Brinton et al., 1987) . Furthermore, long-term use of oral contraceptives may be a cofactor that increases risk of cervical cancer by up to four-fold in women who are positive for cervical HPV DNA (Moreno et al., 2002) . highest as 17.93/100,000/year in Zimbabwe in 2000 (Chokunonga et al., 2000) and lowest as 0.11/100,000/ year in China in 2006 (Chen, 2006) .
Cervical cancer mortality
Four studies reported cervical cancer crude mortality rate (Kalakun and Bozzetti, 2005; Sandagdorj et al., 2010; Naumovic et al., 2015; Wang, 2015) whereas seven studies reported age standardized mortality rate (Sandagdorj et al., 2010; Dikshit et al., 2012; Kuehn et al., 2012; Gonzaga et al., 2013; Pineros et al., 2013; Du et al., 2015; Naumovic Another of the reviewed studies reported that high parity and poor genital hygiene conditions were the main cofactors for cervical cancer in the population with prevalent HPV infections (Bayo et al., 2002) . Therefore, the role of persistent infection with oncogenic types of HPV in the etiology of cervical cancer has encouraged the evaluation of HPV testing as a screening tool (IARC, 1995; Bosch et al., 2002; Franco, 2003) . Cigarette smoking is the only nonsexual behavior consistently and strongly correlated with cervical cancer, independently increasing risk two-to four fold (Winkelstein, 1990) .
In the absence of a nationwide screening program, there are disparities in screening, treatment, and ultimately survival. The variation in study population, sample size and time frame have shown variation in the reported incidence in our review (Chokunonga et al., 2000; Banda et al., 2001; Wabinga, 2002; Sriamporn et al., 2003; Chen, 2006; Gibson et al., 2008; Missaoui et al., 2010; Sandagdorj et al., 2010; Dhillon et al., 2011; Kuehn et al., 2012; Chokunonga et al., 2013; Du et al., 2015) and the IARC country specific estimates of cervical cancer (Ferlay et al., 2013) . The highest age standardized incidence rate is 17.93/100,000/year in Zimbabwe in 2000 which is one of the countries in East Africa having the highest cervical cancer incidence rates.
The age standardized mortality rate was reported highest as 16/100,000/year in India in 2015 among the other LMICs (Pineros et al., 2013) . Also, India has the highest age standardized mortality rates in South-East Asia followed by Myanmar and Nepal (Ferlay et al., 2013 ). An analysis of population-based surveys indicates that coverage of cervical cancer screening in developing countries is 19% compared to 63% in developed countries and ranges from 1% in Bangladesh to 73% in Brazil (Gakidou E, 2009) . Studies have shown that population based screening programs may be an effective method to prevent cervical cancer deaths also in developing countries (Sankaranarayanan et al., 2007) . According to the WHO, 80% to 100% coverage of the target population with Pap smear screening, adequate diagnosis and treatment would allow a 60% to 90% reduction in cervical cancer (Boyle and Levin, 2008) . A large cluster randomized trial from India shows that a single round of HPV screening can significantly reduce the numbers of advanced cervical cancers and deaths from cervical cancer in a low resource setting (Sankaranarayanan et al., 2009) . In addition, studies confirm that vaccination programs containing the seven most common HPV types would prevent about 87% of cervical cancer worldwide (Munoz et al., 2004) .
Unfortunately, the majority of women in developing countries still do not have access to cervical cancer prevention programmes which is resulting in increased cervical cancer disease burden (Ferlay et al., 2013) . Furthermore, low adherence among women regarding screening and diagnosis of chronic non-communicable diseases has been one of the most important factor to be considered for cervical cancer screening and diagnosis in LMICs (Hodgkins and Orbell, 1998; Floyd et al., 2000) , (Shrestha et al., 2013) .
Limitations
Our study is limited to MEDLINE, CINAHL and Scopus database searches. Thus, it may not cover all the studies conducted in this field; particularly those published in non-indexed local journals, non-English publications, and open access platforms not covered by MEDLINE, CINAHL and Scopus. Moreover, we did not assess the publication bias of the articles, as it is not relevant in context of prevalence, incidence and mortality studies. There are chances of considerable under reporting in the prevalence or incidence or mortality rates in our study particularly since the capacity for cancer diagnosis and data capture is limited in LMICs.
In conclusion, the review reported prevalence of cervical cancer as 5.0 per 1,000 in 2012 in Nigeria among the age group 25-64 years and the highest age standardized incidence rate as 17.93/100,000/year in Zimbabwe in 2,000 and lowest as 0.11/100,000/year in China in 2006. Further, the age standardized mortality rate was reported highest as 16/100,000/year in India in 2015 and lowest as 1.8/100,000/year in Colombia in 2013. This review provides useful information for the future prevention and clinical management guidelines on cervical cancer in LMICs, but more importantly reveals the substantial need for further studies on cervical cancer prevalence, incidence and mortality with associated risk factors in LMICs.
